Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Wakako Daido, Takeshi Masuda, Nobuki Imano, Naoko Matsumoto, Kosuke Hamai, Yasuo Iwamoto, Yusuke Takayama, Sayaka Ueno, Masahiko Sumii, Hiroyasu Shoda, Nobuhisa Ishikawa, Masahiro Yamasaki, Yoshifumi Nishimura, Shigeo Kawase, Naoki Shiota, Yoshikazu Awaya, Tomoko Suzuki, Soichi Kitaguchi, Kazunori Fujitaka, Yasushi Nagata, Noboru Hattori
Summary: Interstitial lung disease (ILD) is a life-threatening toxicity caused by chemoradiotherapy and durvalumab. In non-small-cell lung cancer patients, pre-existing interstitial lung abnormalities (ILAs) may be independent risk factors for ILD during treatment with durvalumab. Patients with ILAs should be monitored closely for the development of severe ILD during durvalumab therapy.
Article
Oncology
Tomomi Isono, Kota Iwahori, Masahiro Yanagawa, Yoko Yamamoto, Mari Tone, Miya Haruna, Michinari Hirata, Eriko Fukui, Toru Kimura, Takashi Kanou, Naoko Ose, Soichiro Funaki, Yoshito Takeda, Eiichi Morii, Atsushi Kumanogoh, Yasushi Shintani, Hisashi Wada
Summary: This study aimed to investigate the rationale and adverse events of immunotherapy in NSCLC patients with ILD. T cell profiles and functions in the lung tissues of NSCLC patients were analyzed to provide evidence for the potential mechanism of ICI-related pneumonitis in NSCLC patients with ILD.
Article
Pharmacology & Pharmacy
A. S. Pal, M. Bains, A. Agredo, A. L. Kasinski
Summary: Lung cancer is a major cause of cancer-related deaths, and overcoming resistance to EGFR inhibitors is crucial in the treatment of non-small cell lung cancer. This study identifies the important role of microRNAs in driving resistance to EGFR inhibitors in non-small cell lung cancer cells.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Yanning Wang, Xiaoling Gong, Yuxuan Hu, Qing Yi, Qianning Zhang, Liyun Miao, Yujie Zhou
Summary: The addition of anti-angiogenic drugs may reduce the risk of chemotherapy-related ILD progression in patients with NSCLC-ILD.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Przemyslaw Bieganski, Martina Godel, Chiara Riganti, Daniel Fabio Kawano, Joanna Kopecka, Konrad Kowalski
Summary: A library of 1,4- and 1,5-triazole ferrocenyl derivatives of erlotinib were synthesized and their anticancer activity was studied against erlotinib-sensitive and erlotinib-resistant lung cancer cells. Among the compounds investigated, two isomers showed superior activity against erlotinib-resistant cells, with a mechanism of action different from erlotinib.
BIOORGANIC CHEMISTRY
(2022)
Review
Oncology
Daijiro Harada, Nagio Takigawa
Summary: Retrospective studies support the effectiveness of the strategy of OPD and LAT in treating NSCLC patients with driver mutations, and it is expected to have some effect in patients without driver mutations in certain conditions. After combination therapy of immune checkpoint inhibitors and chemotherapy, LAT with radiotherapy may also have a positive impact.
Review
Oncology
Natsuki Nakagawa, Masanori Kawakami
Summary: The treatment landscape of advanced NSCLC has been transformed by the emergence of ICIs. While some patients benefit from ICI treatment with long survival and mild toxicities, not all patients experience such benefits. Decision-making for ICI treatment is complex due to the lack of head-to-head comparisons, and PD-L1 expression is considered a standard predictive biomarker. Further research is needed to understand the optimal use of ICIs in NSCLC patients with different clinical factors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xianmeng Chen, Daqing Xia, Xuqin Jiang, Lejie Cao, Jay H. Ryu, Xiaowen Hu
Summary: Molecular targeting therapy is the standard of care for ALK-rearranged lung adenocarcinoma. This report presents a case of interstitial lung disease associated with alectinib therapy in a patient with advanced lung adenocarcinoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Yuri Tasaka, Takayuki Honda, Naoki Nishiyama, Toshiharu Tsutsui, Hiroaki Saito, Haruna Watabe, Kazuhiro Shimaya, Akifumi Mochizuki, Shun Tsuyuki, Tatsuo Kawahara, Rie Sakakibara, Takahiro Mitsumura, Tsukasa Okamoto, Masayoshi Kobayashi, Tomoshige Chiaki, Takaaki Yamashita, Yoshikazu Tsukada, Reiko Taki, Yasuto Jin, Hiroyuki Sakashita, Ichirou Natsume, Kazuhito Saitou, Yoshihiro Miyashita, Yasunari Miyazaki
Summary: A study on the use of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients found that while patients with pre-existing interstitial lung disease (ILD) were more prone to checkpoint inhibitor pneumonitis (CIP), their treatment outcomes and survival rates were not inferior to those without ILD.
Article
Oncology
Tairo Kashihara, Yuko Nakayama, Kae Okuma, Ayaka Takahashi, Tomoya Kaneda, Mika Katagiri, Hiroki Nakayama, Yuko Kubo, Kimiteru Ito, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Tetsuo Saito, Hiroyuki Okamoto, Jun Itami, Masahiko Kusumoto, Yuichiro Ohe, Hiroshi Igaki
Summary: This study investigated the prognostic factors of LA-NSCLC patients treated with CCRT plus durvalumab in Japan, and found that pretreatment factors such as ILA, adenocarcinoma, and performance status were correlated with overall survival. PD-L1 expression and ILA score were significantly correlated with cause-specific survival, progression-free survival, and in-field progression-free survival.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Engineering, Biomedical
Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Summary: In this study, a multifunctional superparamagnetic nanotheranostic agent was developed to enhance the efficacy of Erlotinib in EGFR-wt NSCLC. The nanoparticles co-delivered Erlotinib and a VEGF inhibitor (Bev) to EGFR-wt tumors, inhibiting tumor growth and promoting vascular normalization. The tumor engagement of nanoparticles and vascular normalization could be tracked by MRI.
BIOACTIVE MATERIALS
(2022)
Article
Oncology
Rony Laor-Maayany, Gil Goldzweig, Ilanit Hasson-Ohayon, Gil Bar-Sela, Adi Engler-Gross, Michal Braun
SUPPORTIVE CARE IN CANCER
(2020)
Review
Integrative & Complementary Medicine
Harald Matthes, Anja Thronicke, Ralf-Dieter Hofheinz, Erik Baars, David Martin, Roman Huber, Thomas Breitkreuz, Gil Bar-Sela, Daniel Galun, Friedemann Schad
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
(2020)
Article
Oncology
Gil Bar-Sela, Shlomit Bagon, Inbal Mitnik, Svetlana Baziliansky, Avigail Bar-Sella, Olga Vornicova, Tzahala Tzuk-Shina
SUPPORTIVE CARE IN CANCER
(2020)
Review
Oncology
Mahmoud Abu-Amna, Talal Salti, Mona Khoury, Idan Cohen, Gil Bar-Sela
Summary: With the increasing demand for cannabis among cancer patients, there is a clear need for more reliable scientific data and clinical evidence to support its use, along with specific guidelines for dosages and cannabinoid concentrations in products. Physicians should prescribe cannabis cautiously, ensuring thorough evaluation and follow-up response assessment.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Miri Cohen, Dana Yagil, Ariel Aviv, Michal Soffer, Gil Bar-Sela
Summary: This study aimed to assess the experience, perceptions, and reactions of cancer patients during the COVID-19 pandemic using a mixed-methods design. The findings suggest that most cancer patients viewed the pandemic as a major threat, but their level of psychological distress was low. Health experts should pay attention to the emotional and support needs of cancer patients and identify those with high intolerance of uncertainty as a risk factor for psychological distress in times of extreme uncertainty like COVID-19.
JOURNAL OF CANCER SURVIVORSHIP
(2022)
Article
Oncology
Ilit Turgeman, Gil Bar-Sela
Summary: The study aimed to identify characteristics of patients most fitting for treatment in an oncology-dedicated emergency department (OED). Results showed that OED provides efficacious, cancer-focused care suitable for the majority of acute admissions. Careful triage is recommended, as high-risk patients should be referred to the general emergency department (GED) where advanced multidisciplinary management is more readily available.
JCO ONCOLOGY PRACTICE
(2021)
Letter
Oncology
Ilit Turgeman, Gil Bar-Sela
JCO ONCOLOGY PRACTICE
(2021)
Article
Health Care Sciences & Services
Gil Bar-Sela, Aviad Tur-Sinai, Noa Givon-Schaham, Netta Bentur
Summary: The purpose of this study is to determine whether an advance directives (AD) document or an end-of-life discussion between patient and family (DwF) improves cancer patients' likelihood of receiving preferred treatments and dying in their preferred place. The study found that conducting a DwF and having an AD document were significantly associated with treatment consistency and preferred place of death. The study highlights the importance of advance care planning in improving end-of-life care.
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
(2023)
Letter
Oncology
Cohen Idan, Campisi-Pinto Salvatore, Rozenberg Orit, Abaev Ariel, Khoury Marah, Agbaria Dana, Eitam Harel, Colodner Raul, Khoury Mona, Shalabna Hassan, Samih Yousef, Mahamid Camel, Abu-Amna Mahmoud, Bar-Sela Gil
CANCER COMMUNICATIONS
(2022)
Article
Oncology
Idan Cohen, Salvatore Campisi-Pfinto, Orit Rozenberg, Raul Colodner, Gil Bar-Sela
Summary: Since January 2022, high-risk populations in Israel have been advised to receive a fourth dose of the BNT162b2 vaccine for protection against SARS-CoV-2. This study monitored the vaccine-induced immunity among oncology patients undergoing anti-cancer therapy before and after the fourth dose of BNT162b2. The results showed that antibody levels were higher in patients who had breakthrough infections or received the fourth dose, compared to the control group.
Article
Oncology
Michael Schultz, Svetlana Baziliansky, Inbal Mitnik, Nirit Ulitzur, Shay Illouz, Duaa Katra, Simon Givoli, Salvatore Campisi-Pinto, Gil Bar-Sela, Daniela Zalman
Summary: This study found that cancer patients who received services from psychology, social work, and spiritual care had significant impacts on their end-of-life medical outcomes, including reduced aggressive care, increased time after their last treatment, and increased hospice use. These outcomes directly affect improved quality of life and reduced costs.
Article
Social Work
Ora Nakash, Leeat Granek, Michal Cohen, Gil Bar-Sela, David Geffen, Merav Ben David
HEALTH & SOCIAL WORK
(2020)
Article
Health Policy & Services
Sharon R. Sznitman, Victoria Goldberg, Hedva Sheinman-Yuffe, Yuval Zolotov, Ezequiel Flechter, Gil Bar-Sela
PALLIATIVE & SUPPORTIVE CARE
(2020)
Article
Health Policy & Services
Simon Vulfsons, Miriam Ognitz, Gil Bar-Sela, Ayelet Raz-Pasteur, Elon Eisenberg
PALLIATIVE & SUPPORTIVE CARE
(2020)
Article
Health Policy & Services
Michael Schultz, Johanna Czamanski-Cohen, Netta Bentur, Saidah Mohsen-Byadsi, Yoav Artsieli, Gil Bar-Sela
PALLIATIVE & SUPPORTIVE CARE
(2020)